MB
Therapeutic Areas
Regeneron Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dupixent (dupilumab) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 |
| Odronextamab | Relapsed/Refractory Follicular Lymphoma & DLBCL | Phase 3 |
| Pozelimab | Complement 3 Glomerulopathy (C3G) | Phase 3 |
| Garetosmab | Fibrodysplasia Ossificans Progressiva (FOP) | Phase 3 |
| Linvoseltamab | Relapsed/Refractory Multiple Myeloma | Phase 3 |
| Fianlimab + Cemiplimab | Advanced Melanoma (1L adjuvant) | Phase 3 |
| REGN1908-1909 (Fel d 1 mAb) | Cat Allergy | Phase 3 |
| VEGF C-D | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2/3 |
Leadership Team at Regeneron
LS
Leonard S. Schleifer
Board Co-Chair, President and Chief Executive Officer
GD
George D. Yancopoulos
Board Co-Chair, President and Chief Scientific Officer
AM
Andrew Murphy
Executive Vice President, Research and Co-Chief Scientific Officer
NH
Nouhad Husseini
Senior Vice President, Head of Business Development
ZB
Zoran Berkovic
Senior Vice President, Financial Planning and Analysis
LB
Leonard Brooks
Senior Vice President, Treasurer